Form4insider filings, from the source

Insider holders · CIK 0000882104

PDL BIOPHARMA, INC. · PDLI

Every insider with a reported Table I holding at this company, ranked by their last-reported share count. A balance is only as fresh as its filing — the report date sits next to every row on purpose. ← Back to activity

InsiderDirect sharesIndirect sharesTotal reportedLast report (ET)From
John Peter McLaughlinCEO502,108—502,108Jan 9, 2019 · 10:26 am ESTForm 4
Danny J Hart Jr.VP Business Development387,236—387,236Mar 7, 2017 · 8:18 pm ESTForm 4
Paul W SandmanDirector262,800—262,800Jun 12, 2018 · 4:27 pm EDTForm 4
Harold E SelickDirector256,828—256,828Jun 12, 2018 · 4:28 pm EDTForm 4
Jody S LindellDirector256,174—256,174Jun 12, 2018 · 4:30 pm EDTForm 4
Peter S GarciaVice President, CFO225,029—225,029Dec 28, 2018 · 6:30 pm ESTForm 4
Dominique MonnetPresident222,585—222,585Dec 28, 2018 · 6:30 pm ESTForm 4
David W GryskaDirector219,511—219,511Jun 12, 2018 · 4:28 pm EDTForm 4
Paul R EdickDirector214,563—214,563Jun 12, 2018 · 4:29 pm EDTForm 4
Samuel R SaksDirector214,190—214,190Jun 12, 2018 · 4:28 pm EDTForm 4
Christopher Lewis StoneVP, Gen. Counsel & Secretary198,951—198,951Dec 28, 2018 · 6:29 pm ESTForm 4
Steffen PietzkeVP, Finance and CAO139,58720,590160,177Dec 19, 2017 · 8:03 pm ESTForm 4
Elizabeth G. O'FarrellDirector63,291—63,291Jun 25, 2018 · 4:10 pm EDTForm 4
Shlomo YanaiDirector54,348—54,348Jun 12, 2018 · 4:29 pm EDTForm 4
David MontezController and CAO26,719—26,719Jan 30, 2015 · 4:02 pm ESTForm 4
Immune Response BioPharma, Inc.relationship not stated1—1Jun 24, 2015 · 6:20 pm EDTForm 3

Balances come from each insider’s most recent filing that reports a Table I holding; an insider who left the company years ago still appears with their last-known figure and its date. Indirect totals collapse multiple vehicles (trusts, LLCs) into one number — open the filing for the breakdown. Shares as filed, not split-adjusted.